Cholesterol doesn’t announce itself. It’s a quiet, relentless sculptor, carving out heart attacks in arteries long before the first symptom arrives. In a country where one in four deaths is now cardiac, and where young lives fall prey to what was once an old man’s disease, prevention has always been a race against time — and often, against neglect.
Now, a single gene-editing shot might tilt the odds.
CRISPR Therapeutics has unveiled early human trial results for CTX310, a one-time in-vivo CRISPR treatment that turns off a gene called ANGPTL3 in the liver. In its first Phase I trial, a single injection slashed LDL cholesterol and triglyceride levels by over 80% — a number statins and strict diets chase for years, often without catching.
CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results
It matters because in India, where medication adherence is patchy, screenings are irregular, and cardiac arrests claim men and women in their thirties and forties, a one-and-done solution feels like science fiction we urgently need.
No pills, no monthly injections, no prescriptions forgotten on cluttered shelves. Just a silent edit, made once, staying for life.
It’s early, yes. Small trial, careful optimism. But in a country that’s quietly bleeding hearts, CTX310 isn’t just a therapy — it’s a possibility. And those are rare.